Key result
Pravastatin shows comparable major cardiovascular events prevention to atorvastatin with ~18% lower myalgia risk.
Why the study?
This study was conducted to compare the effectiveness and safety of moderate-intensity pravastatin 40 mg/day versus atorvastatin 10 mg/day in patients with dyslipidemia.
Does moderate-intensity pravastatin (40 mg/day) provide comparable effectiveness in preventing major adverse cardiovascular events (MACE) and superior safety compared to moderate-intensity atorvastatin (10 mg/day) in patients with dyslipidemia?
Cohort (n=5,376)
Yes
Does moderate-intensity pravastatin (40 mg/day) provide comparable effectiveness in preventing major adverse cardiovascular events (MACE) and superior safety compared to moderate-intensity atorvastatin (10 mg/day) in patients with dyslipidemia?
In a large multicenter South Korean real-world cohort, moderate-intensity pravastatin (40 mg/day) demonstrated comparable effectiveness to atorvastatin (10 mg/day) for both primary and secondary MACE prevention, while offering a significantly lower risk of myalgia/rhabdomyolysis and AST elevation.
Answers are grounded in this paper and cite their sources.
Supports pravastatin as myalgia-sparing alternative in dyslipidemia; leaves open need for randomized confirmation of MACE equivalence.
AIM: To compare the effectiveness and safety of moderate-intensity pravastatin 40 mg/day and atorvastatin 10 mg/day in patients with dyslipidemia. METHODS: We conducted a retrospective cohort study using electronic health records of 19 million patients across 14 secondary/tertiary hospitals, standardized to a Common Data Model. New users of pravastatin (40 mg/day) and atorvastatin (10 mg/day) were identified. Six distinct cohorts were used to assess the comparative effectiveness in preventing major adverse cardiovascular events (MACE) and the risks of new-onset diabetes mellitus (NODM), myalgia or rhabdomyolysis, and hepatotoxicity (measured by aspartate aminotransferase [AST]/alanine aminotransferase [ALT]). Propensity score matching (PSM) was applied to each cohort for effectiveness and safety analyses, followed by a meta-analysis of hospital-specific results. RESULTS: After PSM, patients were equally assigned to the pravastatin and atorvastatin groups for primary (n = 2,688/group) and secondary MACE prevention (n = 1,258/group) and to assess the risk of NODM (n = 2,391/group), new-onset myalgia or rhabdomyolysis (n = 11,799/group), and hepatotoxicity (AST, n = 4,034/group; ALT, n = 3,655/group). No significant differences were observed in the hazard ratios (HRs) for primary (HR = 0.84; 95% CI, 0.59-1.20) and secondary MACE prevention (HR = 0.89; 95% CI, 0.68-1.16). Similarly, no significant difference was observed in the risk of NODM (HR, 0.99; 95% CI, 0.79-1.23). The risk of new-onset myalgia/rhabdomyolysis (HR = 0.82, 95% CI, 0.69-0.96) and the incidence of abnormal elevations in AST levels (2.35% vs. 3.37%, p<0.05) were significantly lower in the pravastatin group. CONCLUSION: Moderate-intensity pravastatin (40 mg/day) showed comparable effectiveness to moderate-intensity atorvastatin (10 mg/day) in preventing MACE with a more favorable safety profile.
No takes yet. Share an insight, caveat, or question.
Chun et al. (2025) conducted a cohort in Dyslipidemia (n=5,376). Pravastatin vs. Atorvastatin 10 mg/day was evaluated on Composite of major adverse cardiovascular events (MACE: acute myocardial infarction, ischemic stroke, hospitalization due to heart failure, coronary artery revascularization, or all-cause mortality) in primary prevention (HR 0.84, 95% CI 0.59-1.20). Pravastatin /day showed comparable effectiveness to atorvastatin /day for primary and secondary major cardiovascular events prevention with lower myalgia risk.
Synapse has enriched 10 related papers. Consider them for comparative context: